Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients.
Moes DJ, Press RR, Ackaert O, Ploeger BA, Bemelman FJ, Diack C, Wessels JA, van der Straaten T, Danhof M, Sanders JS, Homan van der Heide JJ, Guchelaar HJ, de Fijter JW. Moes DJ, et al. Among authors: ploeger ba. Br J Clin Pharmacol. 2016 Jul;82(1):227-37. doi: 10.1111/bcp.12946. Epub 2016 May 10. Br J Clin Pharmacol. 2016. PMID: 27334415 Free PMC article. Clinical Trial.
Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.
Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, Garmann D, Ploeger B, Eissing T. Snelder N, et al. Clin Pharmacokinet. 2020 Mar;59(3):359-370. doi: 10.1007/s40262-019-00820-x. Clin Pharmacokinet. 2020. PMID: 31583611 Free PMC article. Clinical Trial.
Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies.
Geoerger B, Morland B, Jiménez I, Frappaz D, Pearson ADJ, Vassal G, Maeda P, Kincaide J, Mueller U, Schlief S, Teufel M, Ploeger BA, Cleton A, Agostinho AC, Marshall LV. Geoerger B, et al. Among authors: ploeger ba. Eur J Cancer. 2021 Aug;153:142-152. doi: 10.1016/j.ejca.2021.05.023. Epub 2021 Jun 20. Eur J Cancer. 2021. PMID: 34157616 Free article. Clinical Trial.
Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation.
Sutter G, Frei M, Schultze-Mosgau MH, Petersdorf K, Seitz C, Ploeger BA. Sutter G, et al. Among authors: ploeger ba. Br J Clin Pharmacol. 2022 Feb;88(2):734-741. doi: 10.1111/bcp.15014. Epub 2021 Aug 25. Br J Clin Pharmacol. 2022. PMID: 34327754 Free PMC article.
53 results